Loading...

FDC

NSEI:FDC
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
FDC
NSEI
₹29B
Market Cap
  1. Home
  2. IN
  3. Pharmaceuticals & Biotech
Company description

FDC Limited manufactures and markets pharmaceutical products in India and internationally. The last earnings update was 329 days ago. More info.


Add to Portfolio Compare Print
FDC Share Price and Events
7 Day Returns
-1.6%
NSEI:FDC
0.2%
IN Pharmaceuticals
1.1%
IN Market
1 Year Returns
-36.5%
NSEI:FDC
0.8%
IN Pharmaceuticals
-0.9%
IN Market
FDC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
FDC (FDC) -1.6% -7.9% -4.4% -36.5% -10.9% 22.3%
IN Pharmaceuticals 0.2% 0.8% 4.1% 0.8% -11.1% 36.6%
IN Market 1.1% 1.8% 5.7% -0.9% 41% 72.2%
1 Year Return vs Industry and Market
  • FDC underperformed the Pharmaceuticals industry which returned 0.8% over the past year.
  • FDC underperformed the Market in India which returned -0.9% over the past year.
Price Volatility
FDC
Industry
5yr Volatility vs Market

Value

 Is FDC undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of FDC to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for FDC.

NSEI:FDC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 14.6%
Perpetual Growth Rate 10-Year IN Government Bond Rate 7.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NSEI:FDC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year IN Govt Bond Rate 7.6%
Equity Risk Premium S&P Global 8.6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.729 (1 + (1- 35%) (0.12%))
0.819
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.82
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (0.819 * 8.6%)
14.59%

Discounted Cash Flow Calculation for NSEI:FDC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for FDC is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NSEI:FDC DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (INR, Millions) Source Present Value
Discounted (@ 14.59%)
2019 1,526.00 Analyst x1 1,331.71
2020 2,253.00 Analyst x1 1,715.82
2021 2,391.00 Analyst x1 1,589.08
2022 2,544.69 Est @ 6.43% 1,475.89
2023 2,716.83 Est @ 6.76% 1,375.11
2024 2,907.01 Est @ 7% 1,284.04
2025 3,115.31 Est @ 7.17% 1,200.84
2026 3,342.12 Est @ 7.28% 1,124.25
2027 3,588.15 Est @ 7.36% 1,053.33
2028 3,854.31 Est @ 7.42% 987.41
Present value of next 10 years cash flows ₹13,137.47
NSEI:FDC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ₹3,854.31 × (1 + 7.55%) ÷ (14.59% – 7.55%)
₹58,886.08
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ₹58,886.08 ÷ (1 + 14.59%)10
₹15,085.60
NSEI:FDC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ₹13,137.47 + ₹15,085.60
₹28,223.07
Equity Value per Share
(INR)
= Total value / Shares Outstanding
= ₹28,223.07 / 174.40
₹161.83
NSEI:FDC Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in NSEI:FDC represents 0.99545x of BSE:531599
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.99545x
Value per Share
(Listing Adjusted, INR)
= Value per Share (INR) x Listing Adjustment Factor
= ₹ 161.83 x 0.99545
₹161.09
Value per share (INR) From above. ₹161.09
Current discount Discount to share price of ₹164.15
= -1 x (₹164.15 - ₹161.09) / ₹161.09
-1.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of FDC is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for FDC's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are FDC's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NSEI:FDC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-03-31) in INR ₹9.76
BSE:531599 Share Price ** BSE (2019-04-18) in INR ₹164.9
India Pharmaceuticals Industry PE Ratio Median Figure of 112 Publicly-Listed Pharmaceuticals Companies 20.2x
India Market PE Ratio Median Figure of 2,736 Publicly-Listed Companies 16.34x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of FDC.

NSEI:FDC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BSE:531599 Share Price ÷ EPS (both in INR)

= 164.9 ÷ 9.76

16.9x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • FDC is good value based on earnings compared to the IN Pharmaceuticals industry average.
  • FDC is overvalued based on earnings compared to the India market.
Price based on expected Growth
Does FDC's expected growth come at a high price?
Raw Data
NSEI:FDC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 16.9x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
13.2%per year
India Pharmaceuticals Industry PEG Ratio Median Figure of 32 Publicly-Listed Pharmaceuticals Companies 1.39x
India Market PEG Ratio Median Figure of 584 Publicly-Listed Companies 1.32x

*Line of best fit is calculated by linear regression .

NSEI:FDC PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 16.9x ÷ 13.2%

1.28x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • FDC is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on FDC's assets?
Raw Data
NSEI:FDC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-03-31) in INR ₹73.17
BSE:531599 Share Price * BSE (2019-04-18) in INR ₹164.9
India Pharmaceuticals Industry PB Ratio Median Figure of 133 Publicly-Listed Pharmaceuticals Companies 1.88x
India Market PB Ratio Median Figure of 3,627 Publicly-Listed Companies 1.11x
NSEI:FDC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BSE:531599 Share Price ÷ Book Value per Share (both in INR)

= 164.9 ÷ 73.17

2.25x

* Primary Listing of FDC.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • FDC is overvalued based on assets compared to the IN Pharmaceuticals industry average.
X
Value checks
We assess FDC's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. FDC has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is FDC expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is FDC expected to grow at an attractive rate?
  • FDC's earnings growth is expected to exceed the low risk savings rate of 7.6%.
Growth vs Market Checks
  • FDC's earnings growth is positive but not above the India market average.
  • FDC's revenue growth is positive but not above the India market average.
Annual Growth Rates Comparison
Raw Data
NSEI:FDC Future Growth Rates Data Sources
Data Point Source Value (per year)
NSEI:FDC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 13.2%
NSEI:FDC Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 9.4%
India Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 20.5%
India Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 13.4%
India Market Earnings Growth Rate Market Cap Weighted Average 18.6%
India Market Revenue Growth Rate Market Cap Weighted Average 11.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NSEI:FDC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NSEI:FDC Future Estimates Data
Date (Data in INR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-03-31 14,198 2,968 2,583 1
2020-03-31 12,927 2,808 2,429 1
2019-03-31 11,674 2,208 2,064 1
NSEI:FDC Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2018-03-31 10,751 1,498 1,735
2017-03-31 10,139 1,545 1,885
2016-03-31 9,943 1,743 1,687

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • FDC's earnings are expected to grow by 13.2% yearly, however this is not considered high growth (20% yearly).
  • FDC's revenue is expected to grow by 9.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NSEI:FDC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from FDC Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:FDC Future Estimates Data
Date (Data in INR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-03-31 15.30 15.30 15.30 1.00
2020-03-31 14.40 14.40 14.40 1.00
2019-03-31 12.30 12.30 12.30 1.00
NSEI:FDC Past Financials Data
Date (Data in INR Millions) EPS *
2018-03-31 9.76
2017-03-31 10.60
2016-03-31 9.48

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • FDC is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess FDC's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
FDC has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has FDC performed over the past 5 years?

  • FDC's last earnings update was 329 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare FDC's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient data to establish if FDC's year on year earnings growth rate was positive over the past 5 years.
  • FDC's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • FDC's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
Earnings and Revenue History
FDC's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from FDC Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:FDC Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-03-31 10,750.70 1,735.09 2,677.27
2017-03-31 10,138.66 1,885.32 2,248.89
2016-03-31 9,943.22 1,686.72 2,048.66
2015-03-31 8,893.12 1,481.45 1,705.94
2014-03-31 8,458.54 1,353.18 2,143.50
2013-03-31 7,728.25 1,551.71 1,952.37

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • FDC has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • FDC used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
  • FDC's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess FDC's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
FDC has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is FDC's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up FDC's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • FDC is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • FDC's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of FDC's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 217.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from FDC Company Filings, last reported 1 year ago.

NSEI:FDC Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-03-31 12,761.10 33.17 4,252.87
2017-03-31 12,701.97 36.04 4,636.32
2016-03-31 10,824.69 8.98 3,034.23
2015-03-31 9,363.77 20.66 2,874.35
2014-03-31 8,452.97 26.29 2,533.30
2013-03-31 7,842.44 31.53 2,074.13
  • FDC's level of debt (0.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (0.4% vs 0.3% today).
  • Debt is well covered by operating cash flow (4517.3%, greater than 20% of total debt).
  • FDC earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess FDC's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. FDC has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is FDC's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from FDC dividends. Estimated to be 5.85% next year.
If you bought ₹2,000 of FDC shares you are expected to receive ₹0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate FDC's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate FDC's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NSEI:FDC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
India Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 69 Stocks 0.7%
India Market Average Dividend Yield Market Cap Weighted Average of 1400 Stocks 1.4%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.5%
India Top 25% Dividend Yield 75th Percentile 1.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NSEI:FDC Future Dividends Estimate Data
Date (Data in ₹) Dividend per Share (annual) Avg. No. Analysts
2021-03-31 11.00 1.00
2020-03-31 8.30 1.00
2019-03-31 7.50 1.00
NSEI:FDC Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2018-05-25 0.000 0.000
2017-07-26 2.250 1.040
2017-05-26 2.250 1.220
2016-08-22 2.250 1.073
2016-05-26 2.250 1.218
2015-09-08 2.250 1.101
2015-05-27 2.250 1.347
2014-07-14 2.250 1.474
2014-05-29 2.250 1.709
2013-09-16 2.250 2.027
2012-08-17 2.000 2.242
2011-10-07 2.000 2.456
2010-08-23 1.750 1.764
2009-05-22 1.250 2.052
2009-04-20 1.250 3.603

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as FDC has not reported any payouts.
  • Unable to verify if FDC's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of FDC's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as FDC has not reported any payouts.
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (1.4x coverage).
X
Income/ dividend checks
We assess FDC's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can FDC afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. FDC has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of FDC's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mohan Chandavarkar
COMPENSATION ₹21,103,424
TENURE AS CEO 15 years
CEO Bio

Mr. Mohan Anand Chandavarkar has been the Managing Director of FDC Limited since April 21, 2004 and serves as its Chairman.

CEO Compensation
  • Mohan's compensation has been consistent with company performance over the past year.
  • Mohan's remuneration is about average for companies of similar size in India.
Management Team Tenure

Average tenure of the FDC management team in years:

15
Average Tenure
  • The average tenure for the FDC management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Mohan Chandavarkar

TITLE
Chairman & MD
COMPENSATION
₹21M
TENURE
15 yrs

Nandan Chandavarkar

TITLE
Joint MD & Executive Director
COMPENSATION
₹18M
TENURE
15.1 yrs

Sanjay Jain

TITLE
Chief Financial Officer
TENURE
5.5 yrs

Varsharani Katre

TITLE
Compliance Officer & Company Secretary

Ameya Chandavarkar

TITLE
Executive Director
COMPENSATION
₹12M

Ashok Chandavarkar

TITLE
Executive Director
COMPENSATION
₹15M

Nomita Chandavarkar

TITLE
Executive Director
COMPENSATION
₹6M

Dilip Karnik

TITLE
President of Technical & Operations
Board of Directors Tenure

Average tenure of the FDC board of directors in years:

4.8
Average Tenure
  • The tenure for the FDC board of directors is about average.
Board of Directors

Mohan Chandavarkar

TITLE
Chairman & MD
COMPENSATION
₹21M

Nandan Chandavarkar

TITLE
Joint MD & Executive Director
COMPENSATION
₹18M

Ameya Chandavarkar

TITLE
Executive Director
COMPENSATION
₹12M
TENURE
9.4 yrs

Ashok Chandavarkar

TITLE
Executive Director
COMPENSATION
₹15M
TENURE
9.4 yrs

Nomita Chandavarkar

TITLE
Executive Director
COMPENSATION
₹6M
TENURE
4.8 yrs

Swati Mayekar

TITLE
Independent & Non-Executive Director
COMPENSATION
₹355K
AGE
62
TENURE
4.6 yrs

Uday Gurkar

TITLE
Non-Executive Independent Director
COMPENSATION
₹295K
TENURE
3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
X
Management checks
We assess FDC's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. FDC has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is FDC Limited's (NSE:FDC) CEO Paid At A Competitive Rate?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Mohan Chandavarkar's Compensation Compare With Similar Sized Companies. … Our data indicates that FDC Limited is worth ₹31b, and total annual CEO compensation is ₹21m.

Simply Wall St -

Is FDC Limited's (NSE:FDC) CEO Pay Justified?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Mohan Chandavarkar's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that FDC Limited has a market cap of ₹32b, and is paying total annual CEO compensation of ₹21m.

Simply Wall St -

Can We See Significant Insider Ownership On The FDC Limited (NSE:FDC) Share Register?

The big shareholder groups in FDC Limited (NSE:FDC) have power over the company. … Generally speaking, as a company grows, institutions will increase their ownership. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

Is FDC Limited's (NSE:FDC) 14% ROE Strong Compared To Its Industry?

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … That means that for every ₹1 worth of shareholders' equity, it generated ₹0.14 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Does FDC Limited's (NSE:FDC) PE Ratio Signal A Buying Opportunity?

and want to learn about the link between company’s fundamentals and stock market performance. … While this makes FDC appear like a good stock to buy, you might change your mind after I explain the assumptions behind the P/E ratio. … I will deconstruct the P/E ratio and highlight what you need to be careful of when using the P/E ratio

Simply Wall St -

Does FDC Limited's (NSE:FDC) CEO Pay Reflect Performance?

Understanding how CEOs are incentivised to run and grow their company is an important aspect of investing in a stock. … This is because, if incentives are aligned, more value is created for shareholders which directly impacts your returns as an investor. … CEOs leading companies of similar size and profitability

Simply Wall St -

Why FDC Limited's (NSE:FDC) Investor Composition Impacts Your Returns

Today, I will be analyzing FDC Limited’s (NSE:FDC) recent ownership structure, an important but not-so-popular subject among individual investors. … A company's ownership structure is often linked to its share performance in both the long- and short-term. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders.

Simply Wall St -

What is Behind FDC Limited's (NSE:FDC) Superior ROE?

The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market. … and want a simplistic look at the return on FDC Limited (NSE:FDC) stock. … With an ROE of 13.60%, FDC Limited (NSE:FDC) returned in-line to its own industry which delivered 10.69% over the past year.

Simply Wall St -

How FDC Limited (NSE:FDC) Can Add Value To Your Portfolio

As an investor, I look for investments which does not compromise one fundamental factor for another. … By this I mean, I look at stocks holistically, from their financial health to their future outlook.

Simply Wall St -

FDC Limited's (NSE:FDC) Earnings Dropped -7.97%, How Did It Fare Against The Industry?

Below, I will assess FDC's latest performance announced on 31 March 2018 and weight these figures against its longer term trend and industry movements. … I look at the ‘latest twelve-month’ data, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. … Since these figures may be somewhat short-term, I’ve calculated an annualized five-year figure for FDC's earnings, which stands at ₹1.58B This means while earnings growth was negative against last year, over a longer period of time, FDC's earnings have been increasing on average.

Simply Wall St -

Company Info

Description

FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others; and oral rehydration salts. It provides specialized formulations primarily under the Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm brand names. The company also offers anti-oxidants, balanced energy drinks, and vitamins and nutraceuticals under the MMO3, Enerzal, Humyl, Mum Mum 1, Prosoyal, Simyl-LBW, Simyl-MCT, and Zefrich brands. In addition, it provides various active pharmaceutical ingredients. The company was founded in 1936 and is headquartered in Mumbai, India.

Details
Name: FDC Limited
FDC
Exchange: NSEI
Founded: 1936
₹28,759,068,551
174,403,084
Website: http://www.fdcindia.com
Address: FDC Limited
142-48, Swami Vivekananda Road,
Jogeshwari (West),
Mumbai,
Maharashtra, 400102,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 531599 Equity Shares Mumbai Stock Exchange IN INR 25. Jul 1997
NSEI FDC Equity Shares National Stock Exchange of India IN INR 25. Jul 1997
Number of employees
Current staff
Staff numbers
0
FDC employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 12:48
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/03
Last earnings filing: 2018/05/25
Last earnings reported: 2018/03/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.